Response to "comment on "aldosterone pathway blockade to prevent atrial fibrillation: A systematic review and meta-analysis" by Neefs et al."

Int J Cardiol. 2017 Sep 1:242:23. doi: 10.1016/j.ijcard.2017.03.007.

Authors

J Neefs¹, N W E van den Berg¹, J Limpens¹, W R Berger¹, S M Boekholdt¹, P Sanders², J R de Groot³

Affiliations

¹ Department of Cardiology, Heart Center, Medical Library, Academic Medical Center, Amsterdam, The Netherlands.
² Centre for Heart Rhythm Disorders (CHRD), South Australian Health and Medical Research Institute (SAHMRI), University of Adelaide, Royal Adelaide Hospital, Adelaide, Australia.
³ Department of Cardiology, Heart Center, Medical Library, Academic Medical Center, Amsterdam, The Netherlands. Electronic address: j.r.degroot@amc.uva.nl.

PMID: 28619326
DOI: 10.1016/j.ijcard.2017.03.007

No abstract available

Publication types

Letter
Comment

MeSH terms

Aldosterone*
Angiotensin-Converting Enzyme Inhibitors
Atrial Fibrillation*
Humans
Renin-Angiotensin System

Substances

Angiotensin-Converting Enzyme Inhibitors
Aldosterone